Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma
NCT03824951
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
UNKNOWN
Status
10
Enrollment
INDUSTRY
Sponsor class
Conditions
Refractory B-Cell Lymphoma
Interventions
BIOLOGICAL:
Anti-CD19 iCAR NK Cells
Sponsor
Allife Medical Science and Technology Co., Ltd.
Collaborators
[object Object]